nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—PGR—ovarian cancer	0.426	0.788	CbGaD
Norethindrone—ABCB1—ovarian cancer	0.114	0.211	CbGaD
Norethindrone—CYP3A7—Paclitaxel—ovarian cancer	0.0304	0.109	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0304	0.109	CbGbCtD
Norethindrone—ABCB1—Topotecan—ovarian cancer	0.0299	0.107	CbGbCtD
Norethindrone—CYP3A5—Paclitaxel—ovarian cancer	0.0228	0.0816	CbGbCtD
Norethindrone—CYP3A7—Docetaxel—ovarian cancer	0.022	0.0787	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.022	0.0787	CbGbCtD
Norethindrone—ABCB1—Vinorelbine—ovarian cancer	0.0211	0.0756	CbGbCtD
Norethindrone—CYP3A4—Topotecan—ovarian cancer	0.0179	0.0643	CbGbCtD
Norethindrone—CYP3A5—Docetaxel—ovarian cancer	0.0165	0.059	CbGbCtD
Norethindrone—ABCB1—Paclitaxel—ovarian cancer	0.0148	0.0531	CbGbCtD
Norethindrone—CYP3A4—Vinorelbine—ovarian cancer	0.0126	0.0453	CbGbCtD
Norethindrone—PGR—corpus luteum—ovarian cancer	0.0118	0.246	CbGeAlD
Norethindrone—ABCB1—Docetaxel—ovarian cancer	0.0107	0.0384	CbGbCtD
Norethindrone—PGR—ovarian follicle—ovarian cancer	0.00922	0.193	CbGeAlD
Norethindrone—CYP3A4—Paclitaxel—ovarian cancer	0.00888	0.0318	CbGbCtD
Norethindrone—ABCB1—Doxorubicin—ovarian cancer	0.00799	0.0286	CbGbCtD
Norethindrone—CYP3A4—Docetaxel—ovarian cancer	0.00642	0.023	CbGbCtD
Norethindrone—CYP3A4—Doxorubicin—ovarian cancer	0.00479	0.0172	CbGbCtD
Norethindrone—PGR—oviduct—ovarian cancer	0.00405	0.0846	CbGeAlD
Norethindrone—PGR—myometrium—ovarian cancer	0.0013	0.0271	CbGeAlD
Norethindrone—PGR—epithelium—ovarian cancer	0.00102	0.0212	CbGeAlD
Norethindrone—SHBG—endometrium—ovarian cancer	0.00101	0.0211	CbGeAlD
Norethindrone—PGR—uterine cervix—ovarian cancer	0.00101	0.0211	CbGeAlD
Norethindrone—PGR—decidua—ovarian cancer	0.000961	0.0201	CbGeAlD
Norethindrone—SHBG—gonad—ovarian cancer	0.000939	0.0196	CbGeAlD
Norethindrone—SHBG—uterus—ovarian cancer	0.000933	0.0195	CbGeAlD
Norethindrone—PGR—endometrium—ovarian cancer	0.000912	0.0191	CbGeAlD
Norethindrone—PGR—uterus—ovarian cancer	0.000841	0.0176	CbGeAlD
Norethindrone—SHBG—female reproductive system—ovarian cancer	0.000839	0.0175	CbGeAlD
Norethindrone—SHBG—bone marrow—ovarian cancer	0.000792	0.0165	CbGeAlD
Norethindrone—SHBG—female gonad—ovarian cancer	0.000763	0.0159	CbGeAlD
Norethindrone—SHBG—vagina—ovarian cancer	0.000759	0.0158	CbGeAlD
Norethindrone—PGR—female reproductive system—ovarian cancer	0.000756	0.0158	CbGeAlD
Norethindrone—PGR—female gonad—ovarian cancer	0.000688	0.0144	CbGeAlD
Norethindrone—PGR—vagina—ovarian cancer	0.000683	0.0143	CbGeAlD
Norethindrone—SHBG—testis—ovarian cancer	0.000677	0.0141	CbGeAlD
Norethindrone—PGR—testis—ovarian cancer	0.00061	0.0127	CbGeAlD
Norethindrone—CYP3A5—uterine cervix—ovarian cancer	0.000586	0.0122	CbGeAlD
Norethindrone—ALB—testis—ovarian cancer	0.000559	0.0117	CbGeAlD
Norethindrone—CYP2C19—vagina—ovarian cancer	0.000504	0.0105	CbGeAlD
Norethindrone—Ethynodiol—PGR—ovarian cancer	0.000473	0.0738	CrCbGaD
Norethindrone—Norelgestromin—PGR—ovarian cancer	0.000447	0.0696	CrCbGaD
Norethindrone—Allylestrenol—PGR—ovarian cancer	0.000447	0.0696	CrCbGaD
Norethindrone—PGR—lymph node—ovarian cancer	0.000442	0.00923	CbGeAlD
Norethindrone—Desogestrel—PGR—ovarian cancer	0.00043	0.067	CrCbGaD
Norethindrone—ALB—lymph node—ovarian cancer	0.000405	0.00846	CbGeAlD
Norethindrone—Norgestimate—PGR—ovarian cancer	0.000402	0.0627	CrCbGaD
Norethindrone—ABCB1—myometrium—ovarian cancer	0.0004	0.00836	CbGeAlD
Norethindrone—CYP3A5—female gonad—ovarian cancer	0.0004	0.00835	CbGeAlD
Norethindrone—CYP3A5—vagina—ovarian cancer	0.000397	0.0083	CbGeAlD
Norethindrone—ABCB1—embryo—ovarian cancer	0.000385	0.00804	CbGeAlD
Norethindrone—Quinestrol—ESR1—ovarian cancer	0.000363	0.0565	CrCbGaD
Norethindrone—Etonogestrel—PGR—ovarian cancer	0.000348	0.0543	CrCbGaD
Norethindrone—CYP3A4—female reproductive system—ovarian cancer	0.00033	0.00689	CbGeAlD
Norethindrone—ABCB1—epithelium—ovarian cancer	0.000314	0.00656	CbGeAlD
Norethindrone—ABCB1—uterine cervix—ovarian cancer	0.000312	0.00651	CbGeAlD
Norethindrone—Drospirenone—PGR—ovarian cancer	0.000302	0.047	CrCbGaD
Norethindrone—Ethynodiol—ESR1—ovarian cancer	0.000299	0.0466	CrCbGaD
Norethindrone—ABCB1—decidua—ovarian cancer	0.000297	0.0062	CbGeAlD
Norethindrone—Neoplasm malignant—Epirubicin—ovarian cancer	0.000291	0.00261	CcSEcCtD
Norethindrone—Alopecia—Vinorelbine—ovarian cancer	0.000287	0.00258	CcSEcCtD
Norethindrone—Breast disorder—Paclitaxel—ovarian cancer	0.000285	0.00256	CcSEcCtD
Norethindrone—Breast pain—Epirubicin—ovarian cancer	0.000285	0.00256	CcSEcCtD
Norethindrone—Jaundice cholestatic—Epirubicin—ovarian cancer	0.000283	0.00254	CcSEcCtD
Norethindrone—Amenorrhoea—Epirubicin—ovarian cancer	0.000283	0.00254	CcSEcCtD
Norethindrone—Allylestrenol—ESR1—ovarian cancer	0.000282	0.044	CrCbGaD
Norethindrone—ABCB1—endometrium—ovarian cancer	0.000282	0.00589	CbGeAlD
Norethindrone—Renal impairment—Docetaxel—ovarian cancer	0.000281	0.00252	CcSEcCtD
Norethindrone—Convulsion—Melphalan—ovarian cancer	0.00028	0.00252	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.000279	0.00251	CcSEcCtD
Norethindrone—Mestranol—ESR1—ovarian cancer	0.000275	0.0428	CrCbGaD
Norethindrone—Abdominal distension—Paclitaxel—ovarian cancer	0.000275	0.00247	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000274	0.00246	CcSEcCtD
Norethindrone—Desogestrel—ESR1—ovarian cancer	0.000271	0.0423	CrCbGaD
Norethindrone—Anaphylactic shock—Topotecan—ovarian cancer	0.00027	0.00242	CcSEcCtD
Norethindrone—Neoplasm malignant—Doxorubicin—ovarian cancer	0.000269	0.00242	CcSEcCtD
Norethindrone—Pain in extremity—Docetaxel—ovarian cancer	0.000268	0.0024	CcSEcCtD
Norethindrone—Dyspepsia—Chlorambucil—ovarian cancer	0.000267	0.00239	CcSEcCtD
Norethindrone—Anaphylactic shock—Melphalan—ovarian cancer	0.000264	0.00237	CcSEcCtD
Norethindrone—Oedema—Melphalan—ovarian cancer	0.000264	0.00237	CcSEcCtD
Norethindrone—Breast pain—Doxorubicin—ovarian cancer	0.000264	0.00237	CcSEcCtD
Norethindrone—Migraine—Docetaxel—ovarian cancer	0.000263	0.00236	CcSEcCtD
Norethindrone—Skin disorder—Topotecan—ovarian cancer	0.000262	0.00235	CcSEcCtD
Norethindrone—Jaundice cholestatic—Doxorubicin—ovarian cancer	0.000262	0.00235	CcSEcCtD
Norethindrone—Amenorrhoea—Doxorubicin—ovarian cancer	0.000262	0.00235	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000262	0.00235	CcSEcCtD
Norethindrone—ABCB1—gonad—ovarian cancer	0.000261	0.00546	CbGeAlD
Norethindrone—Fatigue—Chlorambucil—ovarian cancer	0.000261	0.00234	CcSEcCtD
Norethindrone—ABCB1—uterus—ovarian cancer	0.00026	0.00542	CbGeAlD
Norethindrone—Skin disorder—Melphalan—ovarian cancer	0.000257	0.0023	CcSEcCtD
Norethindrone—Norgestimate—ESR1—ovarian cancer	0.000254	0.0396	CrCbGaD
Norethindrone—Photosensitivity reaction—Paclitaxel—ovarian cancer	0.000249	0.00224	CcSEcCtD
Norethindrone—Pulmonary embolism—Epirubicin—ovarian cancer	0.000249	0.00223	CcSEcCtD
Norethindrone—Weight increased—Paclitaxel—ovarian cancer	0.000248	0.00223	CcSEcCtD
Norethindrone—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000248	0.00222	CcSEcCtD
Norethindrone—Levonorgestrel—PGR—ovarian cancer	0.000246	0.0384	CrCbGaD
Norethindrone—Depression—Paclitaxel—ovarian cancer	0.000243	0.00218	CcSEcCtD
Norethindrone—Breast disorder—Docetaxel—ovarian cancer	0.000242	0.00217	CcSEcCtD
Norethindrone—Urticaria—Chlorambucil—ovarian cancer	0.000241	0.00216	CcSEcCtD
Norethindrone—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.00024	0.00215	CcSEcCtD
Norethindrone—Abdominal pain—Chlorambucil—ovarian cancer	0.00024	0.00215	CcSEcCtD
Norethindrone—Renal failure—Paclitaxel—ovarian cancer	0.000239	0.00215	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000239	0.00215	CcSEcCtD
Norethindrone—Myocardial infarction—Paclitaxel—ovarian cancer	0.000239	0.00214	CcSEcCtD
Norethindrone—Dyspepsia—Topotecan—ovarian cancer	0.000237	0.00213	CcSEcCtD
Norethindrone—ABCB1—female reproductive system—ovarian cancer	0.000233	0.00488	CbGeAlD
Norethindrone—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000233	0.00209	CcSEcCtD
Norethindrone—Fatigue—Topotecan—ovarian cancer	0.000233	0.00209	CcSEcCtD
Norethindrone—Dyspepsia—Melphalan—ovarian cancer	0.000232	0.00209	CcSEcCtD
Norethindrone—Anaphylactic shock—Vinorelbine—ovarian cancer	0.000231	0.00207	CcSEcCtD
Norethindrone—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.00023	0.00207	CcSEcCtD
Norethindrone—Pulmonary embolism—Doxorubicin—ovarian cancer	0.00023	0.00207	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000228	0.00205	CcSEcCtD
Norethindrone—Fatigue—Melphalan—ovarian cancer	0.000228	0.00204	CcSEcCtD
Norethindrone—Danazol—PGR—ovarian cancer	0.000224	0.035	CrCbGaD
Norethindrone—Skin disorder—Vinorelbine—ovarian cancer	0.000224	0.00201	CcSEcCtD
Norethindrone—Hypersensitivity—Chlorambucil—ovarian cancer	0.000223	0.002	CcSEcCtD
Norethindrone—Gastrointestinal pain—Topotecan—ovarian cancer	0.000221	0.00198	CcSEcCtD
Norethindrone—ABCB1—bone marrow—ovarian cancer	0.00022	0.0046	CbGeAlD
Norethindrone—Etonogestrel—ESR1—ovarian cancer	0.00022	0.0343	CrCbGaD
Norethindrone—Haemoglobin—Paclitaxel—ovarian cancer	0.00022	0.00197	CcSEcCtD
Norethindrone—Haemorrhage—Paclitaxel—ovarian cancer	0.000218	0.00196	CcSEcCtD
Norethindrone—Asthenia—Chlorambucil—ovarian cancer	0.000217	0.00195	CcSEcCtD
Norethindrone—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000215	0.00193	CcSEcCtD
Norethindrone—Pruritus—Chlorambucil—ovarian cancer	0.000214	0.00192	CcSEcCtD
Norethindrone—Urticaria—Topotecan—ovarian cancer	0.000214	0.00192	CcSEcCtD
Norethindrone—Abdominal pain—Topotecan—ovarian cancer	0.000213	0.00191	CcSEcCtD
Norethindrone—ABCB1—female gonad—ovarian cancer	0.000212	0.00444	CbGeAlD
Norethindrone—ABCB1—vagina—ovarian cancer	0.000211	0.00441	CbGeAlD
Norethindrone—Weight increased—Docetaxel—ovarian cancer	0.000211	0.00189	CcSEcCtD
Norethindrone—Urticaria—Melphalan—ovarian cancer	0.00021	0.00188	CcSEcCtD
Norethindrone—Thrombophlebitis—Epirubicin—ovarian cancer	0.000209	0.00187	CcSEcCtD
Norethindrone—Erythema multiforme—Paclitaxel—ovarian cancer	0.000207	0.00185	CcSEcCtD
Norethindrone—Photosensitivity—Epirubicin—ovarian cancer	0.000206	0.00185	CcSEcCtD
Norethindrone—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000203	0.00183	CcSEcCtD
Norethindrone—Renal failure—Docetaxel—ovarian cancer	0.000203	0.00182	CcSEcCtD
Norethindrone—Myocardial infarction—Docetaxel—ovarian cancer	0.000202	0.00181	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000199	0.00179	CcSEcCtD
Norethindrone—Fatigue—Vinorelbine—ovarian cancer	0.000199	0.00179	CcSEcCtD
Norethindrone—Hypersensitivity—Topotecan—ovarian cancer	0.000199	0.00178	CcSEcCtD
Norethindrone—Immune system disorder—Paclitaxel—ovarian cancer	0.000197	0.00177	CcSEcCtD
Norethindrone—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000195	0.00175	CcSEcCtD
Norethindrone—Hypersensitivity—Melphalan—ovarian cancer	0.000195	0.00175	CcSEcCtD
Norethindrone—Asthenia—Topotecan—ovarian cancer	0.000194	0.00174	CcSEcCtD
Norethindrone—Alopecia—Paclitaxel—ovarian cancer	0.000193	0.00173	CcSEcCtD
Norethindrone—Thrombophlebitis—Doxorubicin—ovarian cancer	0.000193	0.00173	CcSEcCtD
Norethindrone—Vomiting—Chlorambucil—ovarian cancer	0.000193	0.00173	CcSEcCtD
Norethindrone—Mental disorder—Paclitaxel—ovarian cancer	0.000191	0.00172	CcSEcCtD
Norethindrone—Pruritus—Topotecan—ovarian cancer	0.000191	0.00171	CcSEcCtD
Norethindrone—Photosensitivity—Doxorubicin—ovarian cancer	0.00019	0.00171	CcSEcCtD
Norethindrone—Renal impairment—Epirubicin—ovarian cancer	0.00019	0.0017	CcSEcCtD
Norethindrone—Asthenia—Melphalan—ovarian cancer	0.000189	0.0017	CcSEcCtD
Norethindrone—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000189	0.00169	CcSEcCtD
Norethindrone—ABCB1—testis—ovarian cancer	0.000188	0.00393	CbGeAlD
Norethindrone—Flatulence—Paclitaxel—ovarian cancer	0.000187	0.00168	CcSEcCtD
Norethindrone—Purpura—Epirubicin—ovarian cancer	0.000187	0.00168	CcSEcCtD
Norethindrone—Pruritus—Melphalan—ovarian cancer	0.000187	0.00168	CcSEcCtD
Norethindrone—Tension—Paclitaxel—ovarian cancer	0.000187	0.00167	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.000187	0.00167	CcSEcCtD
Norethindrone—Haemoglobin—Docetaxel—ovarian cancer	0.000186	0.00167	CcSEcCtD
Norethindrone—Haemorrhage—Docetaxel—ovarian cancer	0.000185	0.00166	CcSEcCtD
Norethindrone—Hepatitis—Docetaxel—ovarian cancer	0.000185	0.00166	CcSEcCtD
Norethindrone—Nervousness—Paclitaxel—ovarian cancer	0.000185	0.00166	CcSEcCtD
Norethindrone—Urticaria—Vinorelbine—ovarian cancer	0.000183	0.00165	CcSEcCtD
Norethindrone—Abdominal pain—Vinorelbine—ovarian cancer	0.000182	0.00164	CcSEcCtD
Norethindrone—Connective tissue disorder—Docetaxel—ovarian cancer	0.000182	0.00163	CcSEcCtD
Norethindrone—Pain in extremity—Epirubicin—ovarian cancer	0.000181	0.00162	CcSEcCtD
Norethindrone—Nausea—Chlorambucil—ovarian cancer	0.00018	0.00162	CcSEcCtD
Norethindrone—Dizziness—Topotecan—ovarian cancer	0.000178	0.0016	CcSEcCtD
Norethindrone—Migraine—Epirubicin—ovarian cancer	0.000178	0.00159	CcSEcCtD
Norethindrone—Affect lability—Epirubicin—ovarian cancer	0.000178	0.00159	CcSEcCtD
Norethindrone—Renal impairment—Doxorubicin—ovarian cancer	0.000176	0.00158	CcSEcCtD
Norethindrone—Erythema multiforme—Docetaxel—ovarian cancer	0.000175	0.00157	CcSEcCtD
Norethindrone—Purpura—Doxorubicin—ovarian cancer	0.000173	0.00156	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.000173	0.00155	CcSEcCtD
Norethindrone—Vomiting—Topotecan—ovarian cancer	0.000171	0.00154	CcSEcCtD
Norethindrone—Mood swings—Epirubicin—ovarian cancer	0.000171	0.00154	CcSEcCtD
Norethindrone—Rash—Topotecan—ovarian cancer	0.00017	0.00153	CcSEcCtD
Norethindrone—Hypersensitivity—Vinorelbine—ovarian cancer	0.00017	0.00153	CcSEcCtD
Norethindrone—Dermatitis—Topotecan—ovarian cancer	0.00017	0.00153	CcSEcCtD
Norethindrone—Headache—Topotecan—ovarian cancer	0.000169	0.00152	CcSEcCtD
Norethindrone—Vomiting—Melphalan—ovarian cancer	0.000168	0.00151	CcSEcCtD
Norethindrone—Immune system disorder—Docetaxel—ovarian cancer	0.000167	0.0015	CcSEcCtD
Norethindrone—Pain in extremity—Doxorubicin—ovarian cancer	0.000167	0.0015	CcSEcCtD
Norethindrone—Rash—Melphalan—ovarian cancer	0.000167	0.00149	CcSEcCtD
Norethindrone—Dermatitis—Melphalan—ovarian cancer	0.000166	0.00149	CcSEcCtD
Norethindrone—Asthenia—Vinorelbine—ovarian cancer	0.000166	0.00149	CcSEcCtD
Norethindrone—Convulsion—Paclitaxel—ovarian cancer	0.000165	0.00148	CcSEcCtD
Norethindrone—Migraine—Doxorubicin—ovarian cancer	0.000164	0.00148	CcSEcCtD
Norethindrone—Affect lability—Doxorubicin—ovarian cancer	0.000164	0.00148	CcSEcCtD
Norethindrone—Alopecia—Docetaxel—ovarian cancer	0.000164	0.00147	CcSEcCtD
Norethindrone—Pruritus—Vinorelbine—ovarian cancer	0.000163	0.00147	CcSEcCtD
Norethindrone—Breast disorder—Epirubicin—ovarian cancer	0.000163	0.00146	CcSEcCtD
Norethindrone—Mental disorder—Docetaxel—ovarian cancer	0.000162	0.00146	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000161	0.00144	CcSEcCtD
Norethindrone—Nausea—Topotecan—ovarian cancer	0.00016	0.00144	CcSEcCtD
Norethindrone—Mood swings—Doxorubicin—ovarian cancer	0.000158	0.00142	CcSEcCtD
Norethindrone—Abdominal distension—Epirubicin—ovarian cancer	0.000157	0.00141	CcSEcCtD
Norethindrone—Nausea—Melphalan—ovarian cancer	0.000157	0.00141	CcSEcCtD
Norethindrone—Levonorgestrel—ESR1—ovarian cancer	0.000155	0.0242	CrCbGaD
Norethindrone—Oedema—Paclitaxel—ovarian cancer	0.000155	0.00139	CcSEcCtD
Norethindrone—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000155	0.00139	CcSEcCtD
Norethindrone—Dizziness—Vinorelbine—ovarian cancer	0.000153	0.00137	CcSEcCtD
Norethindrone—Breast disorder—Doxorubicin—ovarian cancer	0.000151	0.00135	CcSEcCtD
Norethindrone—Skin disorder—Paclitaxel—ovarian cancer	0.000151	0.00135	CcSEcCtD
Norethindrone—Fluoxymesterone—ESR1—ovarian cancer	0.000148	0.0231	CrCbGaD
Norethindrone—Vomiting—Vinorelbine—ovarian cancer	0.000147	0.00132	CcSEcCtD
Norethindrone—Rash—Vinorelbine—ovarian cancer	0.000145	0.00131	CcSEcCtD
Norethindrone—Dermatitis—Vinorelbine—ovarian cancer	0.000145	0.0013	CcSEcCtD
Norethindrone—Abdominal distension—Doxorubicin—ovarian cancer	0.000145	0.0013	CcSEcCtD
Norethindrone—Headache—Vinorelbine—ovarian cancer	0.000145	0.0013	CcSEcCtD
Norethindrone—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000142	0.00128	CcSEcCtD
Norethindrone—Weight increased—Epirubicin—ovarian cancer	0.000142	0.00127	CcSEcCtD
Norethindrone—Danazol—ESR1—ovarian cancer	0.000142	0.0221	CrCbGaD
Norethindrone—Insomnia—Paclitaxel—ovarian cancer	0.00014	0.00126	CcSEcCtD
Norethindrone—Convulsion—Docetaxel—ovarian cancer	0.00014	0.00125	CcSEcCtD
Norethindrone—Drowsiness—Epirubicin—ovarian cancer	0.000139	0.00125	CcSEcCtD
Norethindrone—Somnolence—Paclitaxel—ovarian cancer	0.000138	0.00124	CcSEcCtD
Norethindrone—Nausea—Vinorelbine—ovarian cancer	0.000137	0.00123	CcSEcCtD
Norethindrone—Renal failure—Epirubicin—ovarian cancer	0.000137	0.00123	CcSEcCtD
Norethindrone—Dyspepsia—Paclitaxel—ovarian cancer	0.000137	0.00123	CcSEcCtD
Norethindrone—ABCB1—lymph node—ovarian cancer	0.000137	0.00285	CbGeAlD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000136	0.00122	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000134	0.0012	CcSEcCtD
Norethindrone—Fatigue—Paclitaxel—ovarian cancer	0.000134	0.0012	CcSEcCtD
Norethindrone—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000132	0.00118	CcSEcCtD
Norethindrone—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000132	0.00118	CcSEcCtD
Norethindrone—Oedema—Docetaxel—ovarian cancer	0.000132	0.00118	CcSEcCtD
Norethindrone—Anaphylactic shock—Docetaxel—ovarian cancer	0.000132	0.00118	CcSEcCtD
Norethindrone—Weight increased—Doxorubicin—ovarian cancer	0.000131	0.00118	CcSEcCtD
Norethindrone—Ethinyl Estradiol—ESR1—ovarian cancer	0.000131	0.0204	CrCbGaD
Norethindrone—Drowsiness—Doxorubicin—ovarian cancer	0.000129	0.00116	CcSEcCtD
Norethindrone—Skin disorder—Docetaxel—ovarian cancer	0.000128	0.00115	CcSEcCtD
Norethindrone—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000127	0.00114	CcSEcCtD
Norethindrone—Renal failure—Doxorubicin—ovarian cancer	0.000127	0.00114	CcSEcCtD
Norethindrone—Haemoglobin—Epirubicin—ovarian cancer	0.000126	0.00113	CcSEcCtD
Norethindrone—Hepatitis—Epirubicin—ovarian cancer	0.000125	0.00112	CcSEcCtD
Norethindrone—Haemorrhage—Epirubicin—ovarian cancer	0.000125	0.00112	CcSEcCtD
Norethindrone—Urticaria—Paclitaxel—ovarian cancer	0.000123	0.00111	CcSEcCtD
Norethindrone—Connective tissue disorder—Epirubicin—ovarian cancer	0.000123	0.0011	CcSEcCtD
Norethindrone—Abdominal pain—Paclitaxel—ovarian cancer	0.000123	0.0011	CcSEcCtD
Norethindrone—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000122	0.00109	CcSEcCtD
Norethindrone—Insomnia—Docetaxel—ovarian cancer	0.000119	0.00107	CcSEcCtD
Norethindrone—Erythema multiforme—Epirubicin—ovarian cancer	0.000118	0.00106	CcSEcCtD
Norethindrone—Somnolence—Docetaxel—ovarian cancer	0.000117	0.00105	CcSEcCtD
Norethindrone—Progesterone—PGR—ovarian cancer	0.000116	0.0181	CrCbGaD
Norethindrone—Haemoglobin—Doxorubicin—ovarian cancer	0.000116	0.00104	CcSEcCtD
Norethindrone—Dyspepsia—Docetaxel—ovarian cancer	0.000116	0.00104	CcSEcCtD
Norethindrone—Haemorrhage—Doxorubicin—ovarian cancer	0.000116	0.00104	CcSEcCtD
Norethindrone—Hepatitis—Doxorubicin—ovarian cancer	0.000116	0.00104	CcSEcCtD
Norethindrone—Hypersensitivity—Paclitaxel—ovarian cancer	0.000114	0.00103	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000114	0.00102	CcSEcCtD
Norethindrone—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000114	0.00102	CcSEcCtD
Norethindrone—Fatigue—Docetaxel—ovarian cancer	0.000113	0.00102	CcSEcCtD
Norethindrone—Immune system disorder—Epirubicin—ovarian cancer	0.000113	0.00101	CcSEcCtD
Norethindrone—Asthenia—Paclitaxel—ovarian cancer	0.000111	0.000999	CcSEcCtD
Norethindrone—Alopecia—Epirubicin—ovarian cancer	0.00011	0.000991	CcSEcCtD
Norethindrone—Pruritus—Paclitaxel—ovarian cancer	0.00011	0.000986	CcSEcCtD
Norethindrone—Mental disorder—Epirubicin—ovarian cancer	0.000109	0.000982	CcSEcCtD
Norethindrone—Erythema multiforme—Doxorubicin—ovarian cancer	0.000109	0.000981	CcSEcCtD
Norethindrone—Progesterone—CYP1B1—ovarian cancer	0.000109	0.0169	CrCbGaD
Norethindrone—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000108	0.000966	CcSEcCtD
Norethindrone—Flatulence—Epirubicin—ovarian cancer	0.000107	0.000962	CcSEcCtD
Norethindrone—Tension—Epirubicin—ovarian cancer	0.000107	0.000958	CcSEcCtD
Norethindrone—Nervousness—Epirubicin—ovarian cancer	0.000106	0.000948	CcSEcCtD
Norethindrone—Immune system disorder—Doxorubicin—ovarian cancer	0.000104	0.000937	CcSEcCtD
Norethindrone—Abdominal pain—Docetaxel—ovarian cancer	0.000104	0.000933	CcSEcCtD
Norethindrone—Testosterone—CYP1B1—ovarian cancer	0.000103	0.016	CrCbGaD
Norethindrone—Dizziness—Paclitaxel—ovarian cancer	0.000103	0.000921	CcSEcCtD
Norethindrone—Alopecia—Doxorubicin—ovarian cancer	0.000102	0.000917	CcSEcCtD
Norethindrone—Mental disorder—Doxorubicin—ovarian cancer	0.000101	0.000909	CcSEcCtD
Norethindrone—Flatulence—Doxorubicin—ovarian cancer	9.91e-05	0.00089	CcSEcCtD
Norethindrone—Tension—Doxorubicin—ovarian cancer	9.87e-05	0.000886	CcSEcCtD
Norethindrone—Vomiting—Paclitaxel—ovarian cancer	9.87e-05	0.000886	CcSEcCtD
Norethindrone—Rash—Paclitaxel—ovarian cancer	9.79e-05	0.000878	CcSEcCtD
Norethindrone—Dermatitis—Paclitaxel—ovarian cancer	9.78e-05	0.000878	CcSEcCtD
Norethindrone—Nervousness—Doxorubicin—ovarian cancer	9.77e-05	0.000877	CcSEcCtD
Norethindrone—Headache—Paclitaxel—ovarian cancer	9.72e-05	0.000873	CcSEcCtD
Norethindrone—Hypersensitivity—Docetaxel—ovarian cancer	9.69e-05	0.00087	CcSEcCtD
Norethindrone—Asthenia—Docetaxel—ovarian cancer	9.44e-05	0.000847	CcSEcCtD
Norethindrone—Convulsion—Epirubicin—ovarian cancer	9.42e-05	0.000845	CcSEcCtD
Norethindrone—Pruritus—Docetaxel—ovarian cancer	9.31e-05	0.000835	CcSEcCtD
Norethindrone—Nausea—Paclitaxel—ovarian cancer	9.22e-05	0.000827	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	9.19e-05	0.000825	CcSEcCtD
Norethindrone—Oedema—Epirubicin—ovarian cancer	8.87e-05	0.000796	CcSEcCtD
Norethindrone—Anaphylactic shock—Epirubicin—ovarian cancer	8.87e-05	0.000796	CcSEcCtD
Norethindrone—Convulsion—Doxorubicin—ovarian cancer	8.72e-05	0.000782	CcSEcCtD
Norethindrone—Dizziness—Docetaxel—ovarian cancer	8.7e-05	0.000781	CcSEcCtD
Norethindrone—Skin disorder—Epirubicin—ovarian cancer	8.62e-05	0.000774	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	8.5e-05	0.000763	CcSEcCtD
Norethindrone—Vomiting—Docetaxel—ovarian cancer	8.36e-05	0.000751	CcSEcCtD
Norethindrone—Rash—Docetaxel—ovarian cancer	8.29e-05	0.000744	CcSEcCtD
Norethindrone—Dermatitis—Docetaxel—ovarian cancer	8.29e-05	0.000744	CcSEcCtD
Norethindrone—Headache—Docetaxel—ovarian cancer	8.24e-05	0.00074	CcSEcCtD
Norethindrone—Anaphylactic shock—Doxorubicin—ovarian cancer	8.21e-05	0.000737	CcSEcCtD
Norethindrone—Oedema—Doxorubicin—ovarian cancer	8.21e-05	0.000737	CcSEcCtD
Norethindrone—Insomnia—Epirubicin—ovarian cancer	8.02e-05	0.00072	CcSEcCtD
Norethindrone—Skin disorder—Doxorubicin—ovarian cancer	7.97e-05	0.000716	CcSEcCtD
Norethindrone—Somnolence—Epirubicin—ovarian cancer	7.89e-05	0.000708	CcSEcCtD
Norethindrone—Nausea—Docetaxel—ovarian cancer	7.81e-05	0.000701	CcSEcCtD
Norethindrone—Dyspepsia—Epirubicin—ovarian cancer	7.81e-05	0.000701	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Epirubicin—ovarian cancer	7.66e-05	0.000688	CcSEcCtD
Norethindrone—Fatigue—Epirubicin—ovarian cancer	7.65e-05	0.000687	CcSEcCtD
Norethindrone—Insomnia—Doxorubicin—ovarian cancer	7.43e-05	0.000667	CcSEcCtD
Norethindrone—Progesterone—ESR1—ovarian cancer	7.34e-05	0.0114	CrCbGaD
Norethindrone—Somnolence—Doxorubicin—ovarian cancer	7.3e-05	0.000655	CcSEcCtD
Norethindrone—Gastrointestinal pain—Epirubicin—ovarian cancer	7.26e-05	0.000651	CcSEcCtD
Norethindrone—Dyspepsia—Doxorubicin—ovarian cancer	7.23e-05	0.000649	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Doxorubicin—ovarian cancer	7.09e-05	0.000636	CcSEcCtD
Norethindrone—Fatigue—Doxorubicin—ovarian cancer	7.08e-05	0.000635	CcSEcCtD
Norethindrone—Urticaria—Epirubicin—ovarian cancer	7.05e-05	0.000633	CcSEcCtD
Norethindrone—Abdominal pain—Epirubicin—ovarian cancer	7.01e-05	0.00063	CcSEcCtD
Norethindrone—Gastrointestinal pain—Doxorubicin—ovarian cancer	6.71e-05	0.000603	CcSEcCtD
Norethindrone—Hypersensitivity—Epirubicin—ovarian cancer	6.54e-05	0.000587	CcSEcCtD
Norethindrone—Urticaria—Doxorubicin—ovarian cancer	6.52e-05	0.000585	CcSEcCtD
Norethindrone—Abdominal pain—Doxorubicin—ovarian cancer	6.49e-05	0.000583	CcSEcCtD
Norethindrone—Asthenia—Epirubicin—ovarian cancer	6.37e-05	0.000571	CcSEcCtD
Norethindrone—Pruritus—Epirubicin—ovarian cancer	6.28e-05	0.000563	CcSEcCtD
Norethindrone—Hypersensitivity—Doxorubicin—ovarian cancer	6.05e-05	0.000543	CcSEcCtD
Norethindrone—Asthenia—Doxorubicin—ovarian cancer	5.89e-05	0.000529	CcSEcCtD
Norethindrone—Dizziness—Epirubicin—ovarian cancer	5.87e-05	0.000527	CcSEcCtD
Norethindrone—Pruritus—Doxorubicin—ovarian cancer	5.81e-05	0.000521	CcSEcCtD
Norethindrone—Vomiting—Epirubicin—ovarian cancer	5.64e-05	0.000506	CcSEcCtD
Norethindrone—Rash—Epirubicin—ovarian cancer	5.59e-05	0.000502	CcSEcCtD
Norethindrone—Dermatitis—Epirubicin—ovarian cancer	5.59e-05	0.000502	CcSEcCtD
Norethindrone—Ethinyl Estradiol—ABCB1—ovarian cancer	5.56e-05	0.00868	CrCbGaD
Norethindrone—Headache—Epirubicin—ovarian cancer	5.56e-05	0.000499	CcSEcCtD
Norethindrone—Dizziness—Doxorubicin—ovarian cancer	5.43e-05	0.000487	CcSEcCtD
Norethindrone—Nausea—Epirubicin—ovarian cancer	5.27e-05	0.000473	CcSEcCtD
Norethindrone—Vomiting—Doxorubicin—ovarian cancer	5.22e-05	0.000469	CcSEcCtD
Norethindrone—Rash—Doxorubicin—ovarian cancer	5.18e-05	0.000465	CcSEcCtD
Norethindrone—Dermatitis—Doxorubicin—ovarian cancer	5.17e-05	0.000464	CcSEcCtD
Norethindrone—Headache—Doxorubicin—ovarian cancer	5.14e-05	0.000462	CcSEcCtD
Norethindrone—Nausea—Doxorubicin—ovarian cancer	4.88e-05	0.000438	CcSEcCtD
Norethindrone—Hydrocortisone—ABCB1—ovarian cancer	3.83e-05	0.00597	CrCbGaD
Norethindrone—Progesterone—ABCB1—ovarian cancer	3.12e-05	0.00486	CrCbGaD
Norethindrone—Testosterone—ABCB1—ovarian cancer	2.95e-05	0.0046	CrCbGaD
Norethindrone—ALB—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	2.05e-05	0.00139	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—ATP7B—ovarian cancer	2.04e-05	0.00139	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—SOD1—ovarian cancer	1.99e-05	0.00136	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—CXCL8—ovarian cancer	1.95e-05	0.00133	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—NME2—ovarian cancer	1.93e-05	0.00132	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—AKT1—ovarian cancer	1.93e-05	0.00131	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	1.89e-05	0.00129	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	1.87e-05	0.00127	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	1.87e-05	0.00127	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—CASP3—ovarian cancer	1.87e-05	0.00127	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL2—ovarian cancer	1.86e-05	0.00127	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—PARP1—ovarian cancer	1.85e-05	0.00126	CbGpPWpGaD
Norethindrone—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—ovarian cancer	1.84e-05	0.00125	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	1.83e-05	0.00125	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	1.81e-05	0.00123	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	1.79e-05	0.00122	CbGpPWpGaD
Norethindrone—ALB—Platelet degranulation—VEGFA—ovarian cancer	1.79e-05	0.00122	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	1.78e-05	0.00121	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—IL6—ovarian cancer	1.77e-05	0.00121	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CYTB—ovarian cancer	1.72e-05	0.00117	CbGpPWpGaD
Norethindrone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—ovarian cancer	1.7e-05	0.00116	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—HDAC6—ovarian cancer	1.68e-05	0.00114	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NME2—ovarian cancer	1.67e-05	0.00113	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—TUBB3—ovarian cancer	1.61e-05	0.0011	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	1.58e-05	0.00108	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—TP53—ovarian cancer	1.58e-05	0.00107	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—BRIP1—ovarian cancer	1.51e-05	0.00103	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PPP1CC—ovarian cancer	1.51e-05	0.00103	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—PPP2R1A—ovarian cancer	1.5e-05	0.00102	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NME2—ovarian cancer	1.49e-05	0.00102	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—YAP1—ovarian cancer	1.48e-05	0.00101	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	1.47e-05	0.001	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NME2—ovarian cancer	1.46e-05	0.000994	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	1.45e-05	0.000991	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—XIAP—ovarian cancer	1.45e-05	0.000991	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—IL6—ovarian cancer	1.44e-05	0.000983	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SMARCA4—ovarian cancer	1.42e-05	0.000966	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	1.41e-05	0.000964	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—SPARC—ovarian cancer	1.41e-05	0.000963	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.41e-05	0.000962	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EREG—ovarian cancer	1.38e-05	0.000942	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	1.38e-05	0.000942	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—PIK3CG—ovarian cancer	1.33e-05	0.000904	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	1.31e-05	0.00089	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.27e-05	0.000864	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYTB—ovarian cancer	1.25e-05	0.000849	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PARP1—ovarian cancer	1.2e-05	0.000821	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	1.17e-05	0.000795	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—PIK3CD—ovarian cancer	1.17e-05	0.000795	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.15e-05	0.000785	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—MYC—ovarian cancer	1.15e-05	0.000783	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—IL6—ovarian cancer	1.15e-05	0.000781	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—BRIP1—ovarian cancer	1.09e-05	0.000742	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PPP1CC—ovarian cancer	1.09e-05	0.000742	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	1.08e-05	0.000734	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYTB—ovarian cancer	1.07e-05	0.000731	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—ESR1—ovarian cancer	1.06e-05	0.000725	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.05e-05	0.000715	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	1.04e-05	0.000709	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.03e-05	0.000704	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—SOD1—ovarian cancer	1.03e-05	0.0007	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PPP2R1A—ovarian cancer	1.02e-05	0.000696	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	1.02e-05	0.000693	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	1.01e-05	0.000691	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—YAP1—ovarian cancer	1.01e-05	0.000689	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PPP2R1A—ovarian cancer	9.77e-06	0.000666	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYTB—ovarian cancer	9.63e-06	0.000656	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	9.44e-06	0.000643	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	9.41e-06	0.000641	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYTB—ovarian cancer	9.4e-06	0.000641	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	9.39e-06	0.00064	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PPP1CC—ovarian cancer	9.38e-06	0.000639	CbGpPWpGaD
Norethindrone—ALB—Metabolism—BRIP1—ovarian cancer	9.38e-06	0.000639	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—IL2—ovarian cancer	9.34e-06	0.000636	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	9.21e-06	0.000627	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	9.11e-06	0.000621	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NME2—ovarian cancer	8.99e-06	0.000612	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	8.96e-06	0.000611	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	8.87e-06	0.000605	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	8.65e-06	0.000589	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PPP1CC—ovarian cancer	8.42e-06	0.000574	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—BRIP1—ovarian cancer	8.42e-06	0.000574	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—FASN—ovarian cancer	8.24e-06	0.000561	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PPP1CC—ovarian cancer	8.22e-06	0.00056	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—BRIP1—ovarian cancer	8.22e-06	0.00056	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—ABCB1—ovarian cancer	8.21e-06	0.00056	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—SLC5A5—ovarian cancer	8.1e-06	0.000552	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	7.93e-06	0.000541	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—SLC2A1—ovarian cancer	7.83e-06	0.000533	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	7.81e-06	0.000532	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TERT—ovarian cancer	7.76e-06	0.000529	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—CAV1—ovarian cancer	7.51e-06	0.000512	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	7.51e-06	0.000511	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CYP1B1—ovarian cancer	7.5e-06	0.000511	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	7.39e-06	0.000504	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—YAP1—ovarian cancer	7.3e-06	0.000498	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	7.19e-06	0.00049	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CAV1—ovarian cancer	7.18e-06	0.000489	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	7.14e-06	0.000487	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	7.03e-06	0.000479	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	7.03e-06	0.000479	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—ESR1—ovarian cancer	6.92e-06	0.000472	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PIK3CG—ovarian cancer	6.84e-06	0.000466	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.83e-06	0.000466	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL6ST—ovarian cancer	6.81e-06	0.000464	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PPP2R1A—ovarian cancer	6.65e-06	0.000453	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	6.64e-06	0.000453	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—APC—ovarian cancer	6.54e-06	0.000446	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PIK3CG—ovarian cancer	6.54e-06	0.000446	CbGpPWpGaD
Norethindrone—ALB—Metabolism—YAP1—ovarian cancer	6.29e-06	0.000429	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.23e-06	0.000424	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	6.2e-06	0.000422	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—ABCB1—ovarian cancer	6.18e-06	0.000421	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.14e-06	0.000418	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	6.1e-06	0.000416	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—TYMS—ovarian cancer	6.07e-06	0.000413	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PIK3CD—ovarian cancer	6.01e-06	0.00041	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—FASN—ovarian cancer	5.95e-06	0.000406	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	5.9e-06	0.000402	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—SLC5A5—ovarian cancer	5.86e-06	0.000399	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYTB—ovarian cancer	5.79e-06	0.000395	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PIK3CD—ovarian cancer	5.75e-06	0.000392	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—MAPK3—ovarian cancer	5.69e-06	0.000388	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—SLC2A1—ovarian cancer	5.66e-06	0.000385	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—YAP1—ovarian cancer	5.65e-06	0.000385	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5.59e-06	0.000381	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—MYC—ovarian cancer	5.54e-06	0.000377	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—YAP1—ovarian cancer	5.51e-06	0.000376	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.47e-06	0.000373	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP1B1—ovarian cancer	5.42e-06	0.00037	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PIK3CB—ovarian cancer	5.24e-06	0.000357	CbGpPWpGaD
Norethindrone—ALB—Metabolism—FASN—ovarian cancer	5.13e-06	0.000349	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—ERBB2—ovarian cancer	5.08e-06	0.000346	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—BRIP1—ovarian cancer	5.06e-06	0.000345	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PPP1CC—ovarian cancer	5.06e-06	0.000345	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	5.06e-06	0.000345	CbGpPWpGaD
Norethindrone—ALB—Metabolism—SLC5A5—ovarian cancer	5.04e-06	0.000344	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MTOR—ovarian cancer	5.01e-06	0.000342	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PIK3CB—ovarian cancer	5.01e-06	0.000342	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	4.98e-06	0.00034	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.91e-06	0.000335	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CAV1—ovarian cancer	4.89e-06	0.000333	CbGpPWpGaD
Norethindrone—ALB—Metabolism—SLC2A1—ovarian cancer	4.87e-06	0.000332	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CXCL8—ovarian cancer	4.82e-06	0.000328	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—IL2—ovarian cancer	4.81e-06	0.000328	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	4.81e-06	0.000328	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.77e-06	0.000325	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CDKN1B—ovarian cancer	4.7e-06	0.000321	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP1B1—ovarian cancer	4.67e-06	0.000318	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CASP3—ovarian cancer	4.61e-06	0.000314	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—FASN—ovarian cancer	4.6e-06	0.000314	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL2—ovarian cancer	4.6e-06	0.000314	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—SLC5A5—ovarian cancer	4.53e-06	0.000309	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—FASN—ovarian cancer	4.49e-06	0.000306	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCND1—ovarian cancer	4.49e-06	0.000306	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ABCB1—ovarian cancer	4.47e-06	0.000304	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CG—ovarian cancer	4.45e-06	0.000303	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CTNNB1—ovarian cancer	4.44e-06	0.000303	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—SLC5A5—ovarian cancer	4.42e-06	0.000301	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—TYMS—ovarian cancer	4.39e-06	0.000299	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—SLC2A1—ovarian cancer	4.37e-06	0.000298	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MMP9—ovarian cancer	4.36e-06	0.000297	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PTEN—ovarian cancer	4.33e-06	0.000295	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.28e-06	0.000292	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—SLC2A1—ovarian cancer	4.27e-06	0.000291	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP1B1—ovarian cancer	4.19e-06	0.000286	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PPP2R1A—ovarian cancer	4.14e-06	0.000282	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.12e-06	0.000281	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP1B1—ovarian cancer	4.09e-06	0.000279	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—VEGFA—ovarian cancer	4.09e-06	0.000279	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—NRAS—ovarian cancer	4.04e-06	0.000275	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CD—ovarian cancer	3.92e-06	0.000267	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—VEGFA—ovarian cancer	3.91e-06	0.000267	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—STAT3—ovarian cancer	3.87e-06	0.000264	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—MAPK3—ovarian cancer	3.87e-06	0.000264	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—NRAS—ovarian cancer	3.86e-06	0.000263	CbGpPWpGaD
Norethindrone—ALB—Metabolism—ABCB1—ovarian cancer	3.85e-06	0.000262	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—AKT1—ovarian cancer	3.84e-06	0.000262	CbGpPWpGaD
Norethindrone—ALB—Metabolism—TYMS—ovarian cancer	3.78e-06	0.000257	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	3.72e-06	0.000253	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MAPK3—ovarian cancer	3.7e-06	0.000252	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.7e-06	0.000252	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—MAPK1—ovarian cancer	3.68e-06	0.000251	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PPP2R1A—ovarian cancer	3.63e-06	0.000247	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MYC—ovarian cancer	3.6e-06	0.000245	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CAV1—ovarian cancer	3.53e-06	0.000241	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MAPK1—ovarian cancer	3.52e-06	0.00024	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EGFR—ovarian cancer	3.52e-06	0.00024	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—KRAS—ovarian cancer	3.48e-06	0.000237	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ABCB1—ovarian cancer	3.45e-06	0.000235	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CB—ovarian cancer	3.41e-06	0.000233	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—YAP1—ovarian cancer	3.4e-06	0.000231	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—TYMS—ovarian cancer	3.39e-06	0.000231	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—KRAS—ovarian cancer	3.33e-06	0.000227	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—TYMS—ovarian cancer	3.31e-06	0.000226	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CG—ovarian cancer	3.22e-06	0.000219	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PIK3CA—ovarian cancer	3.19e-06	0.000218	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TP53—ovarian cancer	3.09e-06	0.000211	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PIK3CA—ovarian cancer	3.06e-06	0.000208	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CAV1—ovarian cancer	3.04e-06	0.000207	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TP53—ovarian cancer	2.96e-06	0.000201	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—HRAS—ovarian cancer	2.96e-06	0.000201	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PTEN—ovarian cancer	2.95e-06	0.000201	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.91e-06	0.000198	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CD—ovarian cancer	2.83e-06	0.000193	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—HRAS—ovarian cancer	2.83e-06	0.000193	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CG—ovarian cancer	2.77e-06	0.000189	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—FASN—ovarian cancer	2.77e-06	0.000189	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CAV1—ovarian cancer	2.73e-06	0.000186	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.72e-06	0.000186	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL6—ovarian cancer	2.71e-06	0.000184	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CAV1—ovarian cancer	2.67e-06	0.000182	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.63e-06	0.000179	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.61e-06	0.000178	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—AKT1—ovarian cancer	2.61e-06	0.000178	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.52e-06	0.000172	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—AKT1—ovarian cancer	2.5e-06	0.00017	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CG—ovarian cancer	2.49e-06	0.00017	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CB—ovarian cancer	2.47e-06	0.000168	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CD—ovarian cancer	2.44e-06	0.000166	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CG—ovarian cancer	2.43e-06	0.000166	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.24e-06	0.000152	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CD—ovarian cancer	2.19e-06	0.000149	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.14e-06	0.000146	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PTEN—ovarian cancer	2.13e-06	0.000145	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CB—ovarian cancer	2.12e-06	0.000145	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CA—ovarian cancer	2.08e-06	0.000142	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.08e-06	0.000141	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—TYMS—ovarian cancer	2.04e-06	0.000139	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.91e-06	0.00013	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.86e-06	0.000127	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PTEN—ovarian cancer	1.84e-06	0.000125	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—AKT1—ovarian cancer	1.7e-06	0.000116	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PTEN—ovarian cancer	1.65e-06	0.000112	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CAV1—ovarian cancer	1.64e-06	0.000112	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PTEN—ovarian cancer	1.61e-06	0.00011	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.5e-06	0.000102	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.5e-06	0.000102	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.32e-06	8.96e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CA—ovarian cancer	1.3e-06	8.82e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—AKT1—ovarian cancer	1.23e-06	8.37e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CA—ovarian cancer	1.16e-06	7.92e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.15e-06	7.81e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.13e-06	7.73e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—AKT1—ovarian cancer	1.06e-06	7.21e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PTEN—ovarian cancer	9.91e-07	6.75e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—AKT1—ovarian cancer	9.5e-07	6.47e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—AKT1—ovarian cancer	9.27e-07	6.32e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CA—ovarian cancer	6.99e-07	4.76e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—AKT1—ovarian cancer	5.71e-07	3.89e-05	CbGpPWpGaD
